» Articles » PMID: 36544856

Recent Approaches on Huntington's Disease (Review)

Abstract

Huntington's disease (HD) is a neurodegenerative disorder characterized by severe motor, cognitive and psychiatric symptoms. Patients of all ages can present with a dysfunction of the nervous system, which leads to the progressive loss of movement control and disabilities in speech, swallowing, communications, etc. The molecular basis of the disease is well-known, as HD is related to a mutated gene, a trinucleotide expansion, which encodes to the huntingtin protein. This protein is linked to neurogenesis and the loss of its function leads to neurodegenerative disorders. Although the genetic cause of the disorder has been known for decades, no effective treatment is yet available to prevent onset or to eliminate the progression of symptoms. Thus, the present review focused on the development of novel methods for the timely and accurate diagnosis of HD in an aim to aid the development of therapies which may reduce the severity of the symptoms and control their progression. The majority of the therapies include gene-silencing mechanisms of the mutated huntingtin gene aiming to suppress its expression, and the use of various substances as drugs with highly promising results. In the present review, the latest approaches on the diagnosis of HD are discussed along with the need for genetic counseling and an up-to-date presentation of the applied treatments.

Citing Articles

Downregulation of Pten Improves Huntington's Disease Phenotype by Reducing Htt Aggregates and Cell Death.

Nisha , Thapliyal D, Gohil B, Modak A, Singh N, Mukherjee C Mol Neurobiol. 2025; .

PMID: 40042729 DOI: 10.1007/s12035-025-04816-6.


Advances in Huntington's Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review.

Aqel S, Ahmad J, Saleh I, Fathima A, Al Thani A, Mohamed W Biology (Basel). 2025; 14(2).

PMID: 40001897 PMC: 11852324. DOI: 10.3390/biology14020129.


UBL3 Interacts with PolyQ-Expanded Huntingtin Fragments and Modifies Their Intracellular Sorting.

Oyama S, Zhang H, Ferdous R, Tomochika Y, Chen B, Jiang S Neurol Int. 2024; 16(6):1175-1188.

PMID: 39449505 PMC: 11503352. DOI: 10.3390/neurolint16060089.


Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives.

Rahimi Darehbagh R, Seyedoshohadaei S, Ramezani R, Rezaei N Eur J Med Res. 2024; 29(1):386.

PMID: 39054501 PMC: 11270957. DOI: 10.1186/s40001-024-01987-1.


Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease.

Shafie A, Ashour A, Anwar S, Anjum F, Hassan M Arch Pharm Res. 2024; 47(6):571-595.

PMID: 38764004 DOI: 10.1007/s12272-024-01499-w.


References
1.
Bonner-Jackson A, Long J, Westervelt H, Tremont G, Aylward E, Paulsen J . Cognitive reserve and brain reserve in prodromal Huntington's disease. J Int Neuropsychol Soc. 2013; 19(7):739-50. PMC: 3720793. DOI: 10.1017/S1355617713000507. View

2.
Squadrone S, Brizio P, Abete M, Brusco A . Trace elements profile in the blood of Huntington' disease patients. J Trace Elem Med Biol. 2019; 57:18-20. DOI: 10.1016/j.jtemb.2019.09.006. View

3.
Aziz N, van der Burg J, Tabrizi S, Landwehrmeyer G . Overlap between age-at-onset and disease-progression determinants in Huntington disease. Neurology. 2018; 90(24):e2099-e2106. PMC: 5996832. DOI: 10.1212/WNL.0000000000005690. View

4.
Andrew S, Goldberg Y, Kremer B, Telenius H, Theilmann J, Adam S . The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet. 1993; 4(4):398-403. DOI: 10.1038/ng0893-398. View

5.
Glidden A, Luebbe E, Elson M, Goldenthal S, Snyder C, Zizzi C . Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology. 2020; 94(19):e2045-e2053. DOI: 10.1212/WNL.0000000000008906. View